What is Lixte Biotechnology Hldgs Inc's earnings per share (EPS)?

Lixte Biotechnology Hldgs Inc (LIXT) reported diluted earnings per share of $-1.26 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lixte Biotechnology Hldgs Inc Financials

LIXT

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Lixte Biotechnology Hldgs Inc (LIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LIXT FY2025 2026-05-14

Lixte’s operating model is still capital-raise funded, and FY2025 spending tilted further from research toward overhead.

FY2025 shows a widening gap between net loss and operating cash burn: the company reported $6.1M of loss but used only -$3.1M of operating cash. Cash ended the year at $5.1M only after $10.3M of financing inflow, so liquidity improved even though the underlying operating model still did not fund itself.

The cost structure changed materially: R&D fell to $255K in FY2025 from $898K in FY2023. Meanwhile, SG&A rose to $4.9M from $2.8M in FY2024, which means the loss base now reflects less scientific spend and more of the cost of maintaining the public-company platform.

The balance sheet looks lightly levered on paper, with debt-to-equity of 0.2x and a current ratio near 3.9x in FY2025, which limits near-term pressure from creditors. But the share count expanded to 8.8M from 2.2M, showing that this cushion was rebuilt mainly through equity issuance rather than through internally generated cash.

Financial Health Signals

Financial Profile 29/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Lixte Biotechnology Hldgs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Lixte Biotechnology Hldgs Inc carries a low D/E ratio of 0.18, meaning only $0.18 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.88, Lixte Biotechnology Hldgs Inc holds $3.88 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 76/100.

Returns

Lixte Biotechnology Hldgs Inc generates a -62.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -433.5% the prior year.

Piotroski F-Score Weak

3/9

Lixte Biotechnology Hldgs Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.51x

For every $1 of reported earnings, Lixte Biotechnology Hldgs Inc generates $0.51 in operating cash flow (-$3.1M OCF vs -$6.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-557.7x

Lixte Biotechnology Hldgs Inc earns $-557.7 in operating income for every $1 of interest expense (-$5.1M vs $9K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$6.1M

YoY-69.5%

Lixte Biotechnology Hldgs Inc reported -$6.1M in net income in fiscal year 2025. This represents a decrease of 69.5% from the prior year.

EPS (Diluted)

$-1.26

Lixte Biotechnology Hldgs Inc earned $-1.26 per diluted share (EPS) in fiscal year 2025. This represents an increase of 20.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.1M

YoY+391.5%

5Y CAGR+0.1%

10Y CAGR+70.0%

Lixte Biotechnology Hldgs Inc held $5.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Lixte Biotechnology Hldgs Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 290.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-62.9%

YoY+370.6pp

5Y CAGR+2.2pp

10Y CAGR+850.3pp

Lixte Biotechnology Hldgs Inc's ROE was -62.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 370.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$255K

YoY-64.9%

5Y CAGR-26.9%

10Y CAGR-19.0%

Lixte Biotechnology Hldgs Inc invested $255K in research and development in fiscal year 2025. This represents a decrease of 64.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

LIXT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$255K-64.9%	$726K-19.1%	$898K-33.4%	$1.3M-22.3%	$1.7M+41.9%	$1.2M
SG&A Expenses	$4.9M+70.5%	$2.8M-32.1%	$4.2M+64.6%	$2.5M-15.8%	$3.0M+295.3%	$765K
Operating Income	-$5.1M-43.0%	-$3.6M+29.8%	-$5.1M+19.3%	-$6.3M+6.1%	-$6.7M-105.7%	-$3.3M
Interest Expense	$9K-45.6%	$17K+3.6%	$16K+82.9%	$9K+19.7%	$7K+101.8%	$4K
Income Tax	$2K	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.1M-69.5%	-$3.6M+29.5%	-$5.1M+19.4%	-$6.3M+6.2%	-$6.7M-106.1%	-$3.3M
EPS (Diluted)	$-1.26	$-1.59+40.2%	$-2.66+33.3%	$-3.99	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$333K	N/A	$51K-16.4%	$61K-33.7%	$91K	N/A	$362K+71.6%	$211K
SG&A Expenses	$1.7M	N/A	$1.8M+145.1%	$714K+16.0%	$615K	N/A	$622K-22.1%	$798K
Operating Income	-$2.0M	N/A	-$1.8M-132.5%	-$775K-9.6%	-$707K	N/A	-$983K+2.6%	-$1.0M
Interest Expense	$3K	N/A	$457-74.8%	$2K-42.3%	$3K	N/A	$1K-74.7%	$4K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.0M	N/A	-$2.0M-155.3%	-$776K-9.3%	-$710K	N/A	-$986K+2.5%	-$1.0M
EPS (Diluted)	$-0.18	N/A	$-0.33-13.8%	$-0.290.0%	$-0.29	N/A	$-0.44+2.2%	$-0.45

LIXT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$12.7M+1011.6%	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M
Current Assets	$5.2M+352.1%	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M
Cash & Equivalents	$5.1M+391.5%	$1.0M-75.3%	$4.2M-21.5%	$5.4M+11.0%	$4.8M-4.8%	$5.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8M+456.8%	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K
Current Liabilities	$1.3M+318.8%	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.7M+1068.3%	$827K-79.3%	$4.0M-22.7%	$5.2M+7.8%	$4.8M-4.4%	$5.0M
Retained Earnings	-$58.1M-11.5%	-$52.1M-7.4%	-$48.5M-11.7%	-$43.4M-17.0%	-$37.1M-22.2%	-$30.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$10.9M-14.7%	$12.7M+134.3%	$5.4M+357.2%	$1.2M-21.5%	$1.5M+32.2%	$1.1M-32.5%	$1.7M-36.4%	$2.7M
Current Assets	$3.4M-34.2%	$5.2M-4.7%	$5.4M+449.0%	$990K	N/A	$1.1M-32.2%	$1.7M-36.7%	$2.7M
Cash & Equivalents	$3.3M-36.3%	$5.1M+76.8%	$2.9M+225.5%	$887K-35.9%	$1.4M+33.3%	$1.0M-36.6%	$1.6M-36.9%	$2.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.7M-4.8%	$1.8M+239.9%	$521K-2.9%	$537K+51.3%	$355K+11.6%	$318K-3.2%	$329K-21.9%	$421K
Current Liabilities	$1.2M-8.1%	$1.3M+155.7%	$521K-2.9%	$537K+51.3%	$355K+11.6%	$318K-3.2%	$329K-21.9%	$421K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.9M-17.8%	$9.7M+96.7%	$4.9M+654.0%	$651K-43.8%	$1.2M+40.1%	$827K-39.5%	$1.4M-39.1%	$2.2M
Retained Earnings	-$60.0M-3.3%	-$58.1M-4.6%	-$55.5M-3.7%	-$53.6M-1.5%	-$52.8M-1.4%	-$52.1M-1.2%	-$51.4M-2.0%	-$50.5M

LIXT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.1M+3.0%	-$3.2M+26.3%	-$4.3M+6.9%	-$4.6M-11.3%	-$4.1M-94.4%	-$2.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$3.2M	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$10.3M	N/A	$3.1M-38.9%	$5.1M+31.9%	$3.9M-15.3%	$4.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.8M-68.3%	-$1.1M-17.4%	-$927K-90.1%	-$487K+14.2%	-$568K+5.0%	-$599K+37.5%	-$958K-16.9%	-$819K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$25K+95.4%	-$535K	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$914K-76.2%	$3.8M-31.0%	$5.6M+55747.7%	-$10K-101.1%	$914K	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LIXT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-62.9%+370.6pp	-433.5%-306.2pp	-127.3%-5.1pp	-122.2%+18.3pp	-140.5%-75.3pp	-65.1%
Return on Assets	-47.7%+265.3pp	-313.1%-195.0pp	-118.1%-4.6pp	-113.5%+18.6pp	-132.1%-69.7pp	-62.4%
Current Ratio	3.88+0.3	3.60-10.1	13.73-0.3	14.05-2.8	16.81-7.3	24.15
Debt-to-Equity	0.18-0.2	0.38+0.3	0.080.0	0.08+0.0	0.06+0.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-25.0%	N/A	-40.3%+78.8pp	-119.1%-57.9pp	-61.2%	N/A	-72.1%-27.1pp	-45.0%
Return on Assets	-18.3%	N/A	-36.4%+28.8pp	-65.3%-18.4pp	-46.9%	N/A	-58.1%-20.2pp	-37.9%
Current Ratio	2.78-1.1	3.88-6.5	10.42+8.6	1.84	N/A	3.60-1.5	5.13-1.2	6.33
Debt-to-Equity	0.21+0.0	0.18+0.1	0.11-0.7	0.82+0.5	0.31-0.1	0.38+0.1	0.24+0.1	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Akari Therapeutics Plc AKTX

$4.2M

Q32 BIO INC QTTB

$106.0M

BOUNDLESS BIO INC BOLD

$34.8M

Propanc Bio PPCB

$1.6M

Allarity ALLR

$23.3M

Frequently Asked Questions

Is Lixte Biotechnology Hldgs Inc profitable?

No, Lixte Biotechnology Hldgs Inc (LIXT) reported a net income of -$6.1M in fiscal year 2025.

What is Lixte Biotechnology Hldgs Inc's return on equity (ROE)?

Lixte Biotechnology Hldgs Inc (LIXT) has a return on equity of -62.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lixte Biotechnology Hldgs Inc's operating cash flow?

Lixte Biotechnology Hldgs Inc (LIXT) generated -$3.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lixte Biotechnology Hldgs Inc's total assets?

Lixte Biotechnology Hldgs Inc (LIXT) had $12.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Lixte Biotechnology Hldgs Inc spend on research and development?

Lixte Biotechnology Hldgs Inc (LIXT) invested $255K in research and development during fiscal year 2025.

How many shares does Lixte Biotechnology Hldgs Inc have outstanding?

Lixte Biotechnology Hldgs Inc (LIXT) had 9M shares outstanding as of fiscal year 2025.

What is Lixte Biotechnology Hldgs Inc's current ratio?

Lixte Biotechnology Hldgs Inc (LIXT) had a current ratio of 3.88 as of fiscal year 2025, which is generally considered healthy.

What is Lixte Biotechnology Hldgs Inc's debt-to-equity ratio?

Lixte Biotechnology Hldgs Inc (LIXT) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lixte Biotechnology Hldgs Inc's return on assets (ROA)?

Lixte Biotechnology Hldgs Inc (LIXT) had a return on assets of -47.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lixte Biotechnology Hldgs Inc's cash runway?

Based on fiscal year 2025 data, Lixte Biotechnology Hldgs Inc (LIXT) had $5.1M in cash against an annual operating cash burn of $3.1M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lixte Biotechnology Hldgs Inc's Piotroski F-Score?

Lixte Biotechnology Hldgs Inc (LIXT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lixte Biotechnology Hldgs Inc's earnings high quality?

Lixte Biotechnology Hldgs Inc (LIXT) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lixte Biotechnology Hldgs Inc cover its interest payments?

Lixte Biotechnology Hldgs Inc (LIXT) has an interest coverage ratio of -557.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Lixte Biotechnology Hldgs Inc?

Lixte Biotechnology Hldgs Inc (LIXT) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.